# Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

> **NCT03684785** · PHASE1,PHASE2 · TERMINATED · sponsor: **Exicure, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Advanced or Metastatic Merkel Cell Carcinoma
- Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
- Advanced or Metastatic Melanoma
- Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** Cavrotolimod
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Cemiplimab
- **DRUG:** Cavrotolimod

## Key facts

- **NCT ID:** NCT03684785
- **Lead sponsor:** Exicure, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-13
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** The study was canceled for administrative reasons.
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03684785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03684785, "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03684785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*